Longeveron (LGVN) Shares Outstanding (2020 - 2026)
Longeveron (LGVN) posted quarterly Shares Outstanding (Entity) of $24.8 billion for Q1 2026, up 65.79% year-over-year from $15.0 billion in Q1 2025, and up 41.02% quarter-over-quarter from $17.6 billion in Q4 2025.
Longeveron (LGVN) Shares Outstanding (2020 - 2026) Analysis & Trends
Longeveron's Shares Outstanding (Entity) history runs 7 years deep, the most recent figure standing at $24.8 billion for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 65.79% year-over-year to $24.8 billion; the TTM figure through Mar 2026 stood at $24.8 billion (up 65.79% YoY), while the FY2025 annual figure was $17.6 billion, up 86.76% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $24.8 billion, up from $17.6 billion in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $24.8 billion in Q1 2026, with the low at $2.1 million in Q1 2022.
- The 5-year median for Shares Outstanding (Entity) is $2.5 million (2024), against an average of $6.7 billion.
- The sharpest annual moves came in 2022 and 2024: Shares Outstanding (Entity) slumped 99.88% in 2022, then soared 643364.8% in 2024.
- Longeveron's Shares Outstanding (Entity) stood at $2.1 million in 2022, then rose by 3.65% to $2.2 million in 2023, then surged by 432897.81% to $9.4 billion in 2024, then jumped by 86.76% to $17.6 billion in 2025, then soared by 41.02% to $24.8 billion in 2026.
- Business Quant data shows LGVN's Shares Outstanding (Entity) at $24.8 billion in Q1 2026, $17.6 billion in Q4 2025, and $18.4 billion in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 62.19 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 398.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 111.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 133.61 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 241.70 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 217.35 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 445.06 Mn |
| 10 | Longeveron | 26.51 Mn | 16.41 Mn | 182,000.00 | 31.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.79 Bn |
| Mar 31, 2026 | 24.79 Bn |
| Dec 31, 2025 | 17.58 Bn |
| Sep 30, 2025 | 18.37 Bn |
| Jun 30, 2025 | 15.01 Bn |
| Mar 31, 2025 | 14.95 Bn |
| Dec 31, 2024 | 9.41 Bn |
| Sep 30, 2024 | 13.63 Bn |
| Jun 30, 2024 | 6.51 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 2.17 Mn |
| Sep 30, 2023 | 2.12 Mn |
| Jun 30, 2023 | 2.11 Mn |
| Mar 31, 2023 | 2.10 Mn |
| Dec 31, 2022 | 2.10 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 2.09 Mn |
| Mar 31, 2022 | 2.09 Mn |
| Dec 31, 2021 | 1.89 Mn |
| Sep 30, 2021 | 1.91 Mn |